Tag: Stem Cell Transplant
Early research at Mayo Clinic using stem cell therapy to treat spinal cord injuries has produced results for one patient that doctors describe as “beyond expectations.”
Spinal cord is the main pathway of communication between brain and peripheral nervous system. Spinal cord injury (SCI) often leads to sensory and motor functional deficits below the injury level, causing severe disability and bringing heavy burden to family and society. Spinal cord injury repair is one of the most challenging medical problems, and no effective therapeutic methods has been developed. The spinal cord is a complex tissue composed of various types of nerve cells, nerve fibers, and blood vessels. After SCI, the injury distance usually reaches several centimeters, resulting in the loss of multiple cells and the interruption of neural connections.
BALDWIN PARK, Calif., Jan. 3, 2019 /PRNewswire/ — StemCyte is pleased to announce that the U.S. Food and Drug Administration (FDA), on December 14, 2018, approved its Phase II Investigational New Drug (IND) application for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury.
During the past 2 decades, cell-based therapies for SCI have been researched in several studies. Replacement of damaged neural tissues and re-establishing connections between the central and peripheral nervous system is vital for the treatment strategy for patients with SCI. Thus, the cells having a potential of self-renewal and differentiating into multiple cell types would be best suited for patients with SCI. Dr Geeta Shroff, director Nutech Mediworld, in a recent research has published report on how human embryonic stem cells (hESC’s) can treat spinal cord injuries (SCI). The findings are first of its kind as the cell line developed was free from animal products and chromosomally stable. The uniqueness about the cell line that makes it exclusive is that the process of cell line was derived from a single hESC which is already patented and published in her earlier reports.
Laura Dominguez-Tauer is a living, breathing example of what it takes to overcome adversity. An oil spill on a San Antonio freeway is blamed for the car crash that sent Laura and her brother directly into a retaining wall in 2001. As she lay tangled in the middle of the car, she heard a paramedic say, “get a neck brace, she has a broken neck.”
“I didn’t feel anything. I couldn’t move my arms, I couldn’t move my hands,”
Laura was paralyzed from the neck down. “I didn’t feel anything. I couldn’t move my arms, I couldn’t move my hands,” Laura said.
During the past 2 decades, cell-based therapies for SCI have been researched in several studies. Replacement of damaged neural tissues and re-establishing connections between the central and peripheral nervous system is vital for the treatment strategy for patients with SCI. According to factsheet of WHO, over 5 hundred thousand people are estimated to suffer from SCI per year. American Spinal Injury Association’s (ASIA) Impairment Scale is a universally accepted scale to assess the SCI, but this scale does not cover all parameters of SCI. Development of new scoring system by Nutech mediworld has the remaining parameters covered in its Nutech Functional score(NFS).
The Miami Project, at the University of Miami Miller School of Medicine, today announced the publication of its first Food and Drug Administration (FDA) approved Phase I clinical trial involving Schwann cells used to repair the damaged spinal cord, in the February issue of the Journal of Neurotrauma. Schwann cells are essential for the repair of nerve damage, and long thought to be able to increase recovery after spinal cord injury. The trial, performed at University of Miami / Jackson Memorial Hospital in Miami, is the first in a series designed to evaluate the safety and feasibility of transplanting autologous human Schwann cells to treat individuals with spinal cord injuries.
StemCells Inc., a California-based biotech company announced that they will stop developing the potential treatment for spinal cord injury after a failed mid-stage clinical trial. The company stock went down to $3.03 per share at the start of the pre-market trade. StemCells reported that they still have $5.5 million in cash as of May 31, but they don’t have a liquidating distribution to their stockholders.
The company said that the amount that they can give to the shareholders depends on the liquid assets, any liabilities, and costs of the wind down.
THE PATHWAY STUDY HAS CLOSED ENROLLMENT AS OF MAY 31 2016!
Researchers are currently evaluating the potential of stem cell transplantation as a treatment for many neurological disorders, including spinal cord injury (SCI). Stem cells are unique from other cells in the body:
- Stem cells can self-renew (make copies of themselves)
- Stem cells can respond to signals within the body and become specialized (this is known as differentiation)
Studying stem cell transplantation for SCI may help us learn if stem cells can help either replace or repair spinal cord cells that were damaged by injury which may in turn improve spinal cord function.
After six months, the patients in the StemCells, Inc. trial being conducted at University of Miami Hospital are demonstrating improvements in both strength and function. They are the first cohort in the Phase II pathway study, led by Allan D. Levi, M.D., Ph.D., professor and Chair of the Department of Neurological Surgery and The Miami Project to Cure Paralysis, which is measuring the effects of implanting stem cells in patients with cervical spinal cord injury (SCI). The assessment of motor function involved using tests of dexterity and grip.
Levi, who is also Chief of Neurosurgery at Jackson Memorial Hospital, was the first investigator to perform a stem cell transplant into the chronically injured cervical spinal cord of a patient.